Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Schaller

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Experimental Hematology|May 16, 2017
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1Nikolas Herold, Sean G Rudd, Kumar Sanjiv, et al.
Materials (Basel, Switzerland)|August 10, 2024
Increased Cytotoxicity of Bimetallic Ultrasmall Silver-Platinum Nanoparticles (2 nm) on Cells and Bacteria in Comparison to Silver Nanoparticles of the Same SizeNatalie Wolff, Nataniel Białas, Kateryna Loza, et al.
The Journal of Physical Chemistry. B|April 19, 2024
The Molecular Footprint of Peptides on the Surface of Ultrasmall Gold Nanoparticles (2 nm) Is Governed by Steric DemandLisa-Sofie Wagner, Oleg Prymak, Torsten Schaller, et al.
Open Biology|November 15, 2013
Insight into the HIV-1 Vif SOCS-box-ElonginBC interactionZhisheng Lu, Julien R C Bergeron, R Andrew Atkinson, et al.
Virology|April 9, 2019
The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxBCindy Buffone, Juliane Kutzner, Silvana Opp, et al.
Journal of Virology|June 29, 2018
Human MxB Protein Is a Pan-herpesvirus Restriction FactorMirjam Schilling, Lorenzo Bulli, Sebastian Weigang, et al.
Environmental Microbiology|December 20, 2024
A CoA-Transferase and Acyl-CoA Dehydrogenase Convert 2-(Carboxymethyl)cyclohexane-1-Carboxyl-CoA During Anaerobic Naphthalene DegradationYachao Kong, Jan Riebe, Malte Feßner, et al.
Journal of Biomedical Science|May 28, 2024
Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virusNarges Seyfizadeh, David Kalbermatter, Thomas Imhof, et al.
Clinical and Translational Science|July 23, 2022
First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteersAntje Blank, Nicolas Hohmann, Marlen Dettmer, et al.
Plos Pathogens|March 23, 2011
HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2Karen E Ocwieja, Troy L Brady, Keshet Ronen, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Experimental Hematology|May 16, 2017
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1Nikolas Herold, Sean G Rudd, Kumar Sanjiv, et al.
Materials (Basel, Switzerland)|August 10, 2024
Increased Cytotoxicity of Bimetallic Ultrasmall Silver-Platinum Nanoparticles (2 nm) on Cells and Bacteria in Comparison to Silver Nanoparticles of the Same SizeNatalie Wolff, Nataniel Białas, Kateryna Loza, et al.
The Journal of Physical Chemistry. B|April 19, 2024
The Molecular Footprint of Peptides on the Surface of Ultrasmall Gold Nanoparticles (2 nm) Is Governed by Steric DemandLisa-Sofie Wagner, Oleg Prymak, Torsten Schaller, et al.
Open Biology|November 15, 2013
Insight into the HIV-1 Vif SOCS-box-ElonginBC interactionZhisheng Lu, Julien R C Bergeron, R Andrew Atkinson, et al.
Virology|April 9, 2019
The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxBCindy Buffone, Juliane Kutzner, Silvana Opp, et al.
Journal of Virology|June 29, 2018
Human MxB Protein Is a Pan-herpesvirus Restriction FactorMirjam Schilling, Lorenzo Bulli, Sebastian Weigang, et al.
Environmental Microbiology|December 20, 2024
A CoA-Transferase and Acyl-CoA Dehydrogenase Convert 2-(Carboxymethyl)cyclohexane-1-Carboxyl-CoA During Anaerobic Naphthalene DegradationYachao Kong, Jan Riebe, Malte Feßner, et al.
Journal of Biomedical Science|May 28, 2024
Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virusNarges Seyfizadeh, David Kalbermatter, Thomas Imhof, et al.
Clinical and Translational Science|July 23, 2022
First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteersAntje Blank, Nicolas Hohmann, Marlen Dettmer, et al.
Plos Pathogens|March 23, 2011
HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2Karen E Ocwieja, Troy L Brady, Keshet Ronen, et al.
Pageof 7